February 25, 2025 (WALTHAM, Mass.) – Thermo Fisher Scientific Inc. has announced its agreement to acquire Solventum’s Purification & Filtration business for approximately $4.1 billion in cash. Solventum’s business, a global leader in purification and filtration technologies, serves biologics production, medical technologies, and industrial applications, employing around 2,500 people worldwide and generating about $1 billion in revenue in 2024.
“The addition of Solventum’s business is an outstanding strategic fit and will create significant value for our customers and shareholders,” said Marc N. Casper, chairman, president, and CEO of Thermo Fisher.
The acquisition complements Thermo Fisher’s bioproduction portfolio, which includes cell culture media and single-use technologies, by expanding its capabilities in upstream and downstream workflows for biologics development and manufacturing. The transaction is expected to close by the end of 2025, subject to customary closing conditions and regulatory approvals, after which Solventum’s Purification & Filtration business will become part of Thermo Fisher's Life Sciences Solutions segment.
Key Points:
- Acquisition price: ~$4.1 billion in cash
- Solventum’s Purification & Filtration business operates globally across Americas, Europe, Middle East, Africa, and Asia-Pacific
- Workforce: ~2,500 employees; 2024 revenue: ~$1 billion
- Strategic fit: Enhances Thermo Fisher’s bioproduction offerings, covering upstream and downstream biologics workflows
- Expected financial impact: Mid- to high-single digit organic growth; ~$125 million of operating synergies by year five; initial year dilutive EPS of $0.06, accretive by $0.28 excluding financing costs
- Advisors: WilmerHale (deal counsel) and Wells Fargo (financial advisor)
- Transaction completion expected by end of 2025, subject to regulatory approvals
